VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

Por Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C, Smit, E F
Publicado em 2012

CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

Por Vroling, L, Lind, J S W, de Haas, R R, Verheul, H M W, van Hinsbergh, V W M, Broxterman, H J, Smit, E F
Publicado em 2010